Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Changes in functional outcome over five years after stroke.

Rejnö Å, Nasic S, Bjälkefur K, Bertholds E, Jood K.

Brain Behav. 2019 Jun;9(6):e01300. doi: 10.1002/brb3.1300. Epub 2019 May 7.

2.

Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study.

Langhorne P, O'Donnell MJ, Chin SL, Zhang H, Xavier D, Avezum A, Mathur N, Turner M, MacLeod MJ, Lopez-Jaramillo P, Damasceno A, Hankey GJ, Dans AL, Elsayed A, Mondo C, Wasay M, Czlonkowska A, Weimar C, Yusufali AH, Hussain FA, Lisheng L, Diener HC, Ryglewicz D, Pogosova N, Iqbal R, Diaz R, Yusoff K, Oguz A, Wang X, Penaherrera E, Lanas F, Ogah OS, Ogunniyi A, Iversen HK, Malaga G, Rumboldt Z, Magazi D, Nilanont Y, Rosengren A, Oveisgharan S, Yusuf S; INTERSTROKE collaborators.

Lancet. 2018 May 19;391(10134):2019-2027. doi: 10.1016/S0140-6736(18)30802-X. Epub 2018 May 17.

PMID:
29864018
3.

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.

Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators; ROCKET AF Steering Committee Investigators.

J Am Heart Assoc. 2016 Mar 8;5(3):e002197. doi: 10.1161/JAHA.115.002197.

4.

Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.

Mair G, von Kummer R, Morris Z, von Heijne A, Bradey N, Cala L, Peeters A, Farrall AJ, Adami A, Potter G, Cohen G, Sandercock PA, Lindley RI, Wardlaw JM; IST-3 Collaborative Group.

Neurology. 2016 Jan 12;86(2):118-25. doi: 10.1212/WNL.0000000000002236. Epub 2015 Dec 9.

5.

Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).

Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigators.

Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3. Erratum in: Circulation. 2018 Dec 18;138(25):e783.

6.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators.

N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.

7.

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A.

Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Epub 2012 May 23. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

8.

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.

Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W; ROCKET AF Steering Committee Investigators.

Lancet Neurol. 2012 Apr;11(4):315-22. doi: 10.1016/S1474-4422(12)70042-X. Epub 2012 Mar 7.

PMID:
22402056
9.

Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.

Sandercock P, Lindley R, Wardlaw J, Dennis M, Innes K, Cohen G, Whiteley W, Perry D, Soosay V, Buchanan D, Venables G, Czlonkowska A, Kobayashi A, Berge E, Slot KB, Murray V, Peeters A, Hankey GJ, Matz K, Brainin M, Ricci S, Cantisani TA, Gubitz G, Phillips SJ, Antonio A, Correia M, Lyrer P, Kane I, Lundstrom E; IST-3 collaborative group.

Trials. 2011 Nov 30;12:252. doi: 10.1186/1745-6215-12-252.

10.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators.

N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.

11.

[A letter requesting lung scintigraphy. Clinical follow up or rough marketing?].

Bertholds E.

Lakartidningen. 2011 May 25-31;108(21):1169. Swedish. No abstract available.

PMID:
21812239
12.

Discarding heparins as treatment for progressive stroke in Sweden 2001 to 2008.

Eriksson M, Stecksén A, Glader EL, Norrving B, Appelros P, Hulter Åsberg K, Stegmayr B, Terént A, Asplund K; Riks-Stroke Collaboration.

Stroke. 2010 Nov;41(11):2552-8. doi: 10.1161/STROKEAHA.110.597724. Epub 2010 Oct 7.

PMID:
20930151
13.

[The lean market is not suitable for health care].

Bertholds E.

Lakartidningen. 2010 Jun 9;107(23):1560-1. Swedish. No abstract available.

PMID:
20617780
14.

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.

O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S; INTERSTROKE investigators.

Lancet. 2010 Jul 10;376(9735):112-23. doi: 10.1016/S0140-6736(10)60834-3. Epub 2010 Jun 17.

PMID:
20561675
15.

Patient dissatisfaction with acute stroke care.

Asplund K, Jonsson F, Eriksson M, Stegmayr B, Appelros P, Norrving B, Terént A, Asberg KH; Riks-Stroke Collaboration.

Stroke. 2009 Dec;40(12):3851-6. doi: 10.1161/STROKEAHA.109.561985. Epub 2009 Oct 22.

PMID:
19850895
16.

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.

Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group.

Lancet Neurol. 2008 Oct;7(10):875-84. doi: 10.1016/S1474-4422(08)70198-4. Epub 2008 Aug 29. Erratum in: Lancet Neurol. 2008 Nov;7(11):985.

17.

Telmisartan to prevent recurrent stroke and cardiovascular events.

Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group.

N Engl J Med. 2008 Sep 18;359(12):1225-37. doi: 10.1056/NEJMoa0804593. Epub 2008 Aug 27.

18.

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.

Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group.

N Engl J Med. 2008 Sep 18;359(12):1238-51. doi: 10.1056/NEJMoa0805002. Epub 2008 Aug 27.

19.

[Health care and market economics are not compatible].

Bertholds E.

Lakartidningen. 2008 Apr 2-8;105(14):1030-1; author reply 1031. Swedish. No abstract available.

PMID:
18478756
20.

[Competent physicians, ECT and the risk of a blow].

Bertholds E.

Lakartidningen. 2008 Jan 23-29;105(4):230-1. Swedish. No abstract available.

PMID:
18306828

Supplemental Content

Loading ...
Support Center